Xaira Therapeutics
Founded Year
2023Stage
Series A | AliveTotal Raised
$1BLast Raised
$500M | 1 yr agoAbout Xaira Therapeutics
Xaira Therapeutics focuses on revolutionizing drug research and development within the biopharmaceutical industry through the use of artificial intelligence. The company offers a platform designed to enhance the drug discovery process, aiming to streamline and improve the efficiency of developing new therapeutics. Xaira Therapeutics primarily serves the biopharmaceutical sector with innovative solutions to accelerate drug R&D. It was founded in 2023 and is based in San Francisco, California.
Loading...
Loading...
Research containing Xaira Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Xaira Therapeutics in 3 CB Insights research briefs, most recently on Mar 11, 2025.
Jan 16, 2025 report
State of Digital Health 2024 Report
Expert Collections containing Xaira Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Xaira Therapeutics is included in 5 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,270 items
Generative AI
1,298 items
Companies working on generative AI applications and infrastructure.
Digital Health
11,305 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Artificial Intelligence
7,221 items
AI in drug discovery
504 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
Latest Xaira Therapeutics News
Mar 12, 2025
2024年、グローバルで超大型の資金調達に成功した未上場スタートアップの顔ぶれを見ると、米Xaira Therapeutics（ザイラ・セラピューティクス）社（2024年の調達額は10億ドル、以下同）、米Kailera Therapeutics（カイレラ・セラピューティクス）社（4億ドル）、米Formation Bio（フォーメーション・バイオ）社（3億7200万ドル）、米Candid Therapeutics（キャンディド・セラピューティクス）社（3億7000万ドル）と、AI創薬、肥満症治療薬、自己免疫疾患治療薬などを開発する企業が並びます。もっともそれらの企業が手掛けているのは、低分子薬、ペプチド医薬、蛋白質・抗体医薬と、いずれも旧来のモダリティが中心。比較的患者数の多い疾患に対して開発を進めやすいことや、既存薬と類似の機序を有する開発品を扱っていることから、超大型の資金調達が実現したと推察されます。
Xaira Therapeutics Frequently Asked Questions (FAQ)
When was Xaira Therapeutics founded?
Xaira Therapeutics was founded in 2023.
Where is Xaira Therapeutics's headquarters?
Xaira Therapeutics's headquarters is located at San Francisco.
What is Xaira Therapeutics's latest funding round?
Xaira Therapeutics's latest funding round is Series A.
How much did Xaira Therapeutics raise?
Xaira Therapeutics raised a total of $1B.
Who are the investors of Xaira Therapeutics?
Investors of Xaira Therapeutics include Foresite Capital, ARCH Venture Partners, RSquared, NEA Partners, Lightspeed Venture Partners and 11 more.
Loading...
Loading...